Company profile
cbdMD, Inc.
AMEX: YCBD · Healthcare · Drug Manufacturers - Specialty & Generic
#549 of 1,418 Healthcare companies by revenue36th-percentile growth
EA Score
49DFH 59DQ 38GM 46SS 45
v0.1 · 65/100 weight · provisional
↑ growth stability, balance-sheet leverage · ↓ filing timeliness, 3-yr revenue growth
Methodology →Revenue TTM
$20.9M
Rev growth YoY (TTM)
+10.0%
Net income (FY)
-$2.0M
Employees
42
as of 2026-08-23
Market cap
$5.3M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$19.2M$19.2M2025
Net income-$2.0M-$2.0M2025
Operating income-$2.2M-$2.2M2025
Total assets$10.4M$10.4M2025
Liabilities$3.2M$3.2M2025
Equity$7.2M$7.2M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY22
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is cbdMD, Inc.’s revenue?
cbdMD, Inc. booked $19.2M in FY2025 revenue, contracting 3.7% year over year — slower than 64% of Healthcare companies we track, at a -10.6% net margin.
Peers · Healthcare
Carisma Therapeutics, Inc.——Sonoma Pharmaceuticals, Inc.60CAvem Health Partners, Inc.——Precision Optics Corporation, Inc.61CLENZ Therapeutics, Inc.48DViaDerma, Inc.——Neighbors
Mecklenburg →Key facts
CEOT. Ronan Kennedy
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersCharlotte, NC
ExchangeAMEX: YCBD
Employees42
IPO date2017-11-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.